The American Medical Association has granted a new Category III Current Procedural Terminology (CPT) code for Lumicell’s intraoperative fluorescence imaging margin assessment.

Planned to be effective from 1 January 2025, the add-on code 0945T will facilitate the reporting of the use of Lumicell's LUMISIGHT optical imaging agent and Lumicell direct visualisation system (DVS), a fluorescence imaging device, by physicians.

The CPT coding is intended to provide a uniform language that precisely describes diagnostic, medical, and testing services for physicians and other healthcare providers.

LUMISIGHT and Lumicell DVS are together referred to as LumiSystem.

LumiSystem is designed to aid surgeons during breast cancer lumpectomy procedures.

With an 84% diagnostic accuracy rate, LumiSystem is said to be the first system that allows surgeons to scan the breast cavity in real time to identify and eliminate remaining cancerous tissue.

Lumicell president and chief operating officer Howard Hechler said: “This is an important milestone for providers who offer this new adjunctive treatment option to their patients with breast cancer undergoing lumpectomy.

“The Category III code will enable wider commercial access to LumiSystem by facilitating future reimbursement from US government payors and commercial health insurance companies.”

LumiSystem is indicated for use as an adjunct in the intraoperative detection of cancerous tissue within the resection cavity during breast cancer lumpectomy surgery in adults.

Lumicell plans to make it commercially available in the fourth quarter of the current year.

In April, Lumicell secured new drug application approval for the LUMISIGHT agent and a premarket approval application for Lumicell DVS from the US Food and Drug Administration.